Discussion of Real-World Myeloma Care Emphasizes Value of Personalized Medicine
Samer A. Al’Hadidi, MD, discusses the importance of personalized medicine in patients with multiple myeloma.
Samer A. Al’Hadidi, MD, assistant professor in the Department of Internal Medicine — Division of Hematology and Oncology at UAMS Winthrop P. Rockefeller Cancer Institute in Little Rock, Arkansas, discusses the importance of personalized medicine in patients with multiple myeloma.
At a Case-Based Roundtable event, Al’Hadidi moderated a discussion on newly diagnosed and relapsed multiple myeloma cases. One of his takeaways was that participants discussed their patients in clinical practice which differ from those who benefited from regimens proven efficacious in clinical trials such as frontline quadruplet combinations and chimeric antigen receptor T-cell therapies.
Participants brought up patients who may have issues with caregiver availability, distance from care centers, and social events that prevent them from receiving intensive treatments. Al’Hadidi said this is an important reminder that each patient’s characteristics are different and may lead the treating physician to seek therapies that have less logistical obstacles or fewer toxicities. The discussion helped explore what factors outside trial data affect patients in clinic and how physicians can select the optimal therapy.
TRANSCRIPTION:
0:10 | I think these case-based events are very important because they actually provide data on patients that you can see in the clinical practice where they differ from patients who are enrolled in clinical trials and may not be really the patients you read about. They may be different. And we always think about what we call personalized medicine, and that is really true, because there are patients, for example, who may have issues with caregiver. They may have distance from the treating location where they get their treatments. They may also have some social events in their life that prevent them from doing, for example, an intensive treatment at a given time.
0:50 | So I think those discussions are very important, because each patient is a scenario that we need to take it by its characteristics, and decide on what will be best. So such opportunities to discuss such patients are important.
So you can see many of the attendees discussing some of their own cases they see and the challenges they find. And that brings up actually, more brainstorming on what will be best for this given patient. That may not be necessarily the thing that is done on a clinical trial basis, but rather on how you treat patients in clinic.
Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison
February 4th 2025During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.
Read More
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
